FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)
The FDA has approved a supplemental application for QTERN, a combination of dapagliflozin and saxagliptin.
Published: July 23, 2026
Updated: July 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Diabetes / SGLT2 Inhibitor / DPP-4 Inhibitor
Company: AstraZeneca
Asset: QTERN
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
AstraZeneca
Asset
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of the supplemental application for QTERN enhances AstraZeneca's competitive positioning in the diabetes market. This approval may influence market dynamics and necessitates strategic responses from other companies in the sector.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for market uptake and any subsequent competitive responses from other diabetes therapies.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.